Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest’s Solomon Holding Firm As Icahn Presses Second Consecutive Proxy Fight

This article was originally published in The Pink Sheet Daily

Executive Summary

In July 9 letter to Icahn, Forest CEO asks why the activist investor hasn’t offered strategic ideas, rather than threaten another fight over board control.

You may also be interested in...

Forest’s Board Grows, As Icahn Gains Second Director’s Seat

Dissident shareholder Carl Icahn will have some influence on the succession process as the New York drugmaker seeks a replacement for its retiring octogenarian CEO. Forest still needs to compensate for the loss of blockbuster antidepressant Lexapro, and could consider a sale or dramatic restructuring.

Carl Icahn’s Partial Victory In Battle For Forest: One Board Seat

Primary care-focused pharma reports that preliminary voting results show former OSI executive Pierre Legault was elected to the Forest board, replacing long-time member and outgoing compensation committee Chairman Dan Goldwasser.

Tudorza’s Delivery System Key To Positioning For COPD Maintenance

Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts